Loxo Oncology Inc (LOXO.OQ)
LOXO.OQ on NASDAQ Stock Exchange Global Market
177.19USD
4:00pm EDT
177.19USD
4:00pm EDT
Change (% chg)
$-1.55 (-0.87%)
$-1.55 (-0.87%)
Prev Close
$178.74
$178.74
Open
$178.56
$178.56
Day's High
$178.91
$178.91
Day's Low
$175.75
$175.75
Volume
79,585
79,585
Avg. Vol
171,132
171,132
52-wk High
$208.78
$208.78
52-wk Low
$69.06
$69.06
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 38.43 | -0.119 |
| FY 2017 | Dec '17 | 21.30 | -0.688 |
| Sep '17 | 0.00 | -2.454 | |
| Jun '17 | 0.00 | -1.143 | |
| Mar '17 | 0.00 | -0.956 | |
| FY 2016 | Dec '16 | 0.00 | -1.260 |
| Sep '16 | 0.00 | -0.819 | |
| Jun '16 | 0.00 | -0.773 | |
| Mar '16 | 0.00 | -0.593 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 5 | 31.38 | 50.00 | 0.00 | 0.00 |
| Quarter Ending Dec-18 | 5 | 40.99 | 111.60 | 2.90 | 30.00 |
| Year Ending Dec-18 | 4 | 146.37 | 250.00 | 41.40 | 40.48 |
| Year Ending Dec-19 | 3 | 63.00 | 125.00 | 15.60 | 118.71 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 5 | -0.52 | 0.00 | -1.44 | -- |
| Quarter Ending Dec-18 | 5 | -0.42 | 1.77 | -1.35 | -- |
| Year Ending Dec-18 | 5 | -1.72 | 1.80 | -4.38 | -4.84 |
| Year Ending Dec-19 | 5 | -3.87 | -0.30 | -10.38 | -2.36 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 212.74 | 32.86 | |
| P/E High - Last 5 Yrs. | -- | 283.39 | 47.09 | |
| P/E Low - Last 5 Yrs. | -- | 96.61 | 24.92 | |
| Beta | 2.35 | 0.76 | 0.81 | |
| Price to Sales (TTM) | 89.51 | 257.41 | 8.16 | |
| Price to Book (MRQ) | 13.97 | 20.98 | 4.20 | |
| Price to Tangible Book (MRQ) | 13.91 | 27.14 | 6.23 | |
| Price to Cash Flow (TTM) | -- | 126.87 | 22.15 | |
| % Owned Institutions | -- | 0.00 | 0.00 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.36 | 1.73 | |
| Dividend Yield - 5 Year Avg | -- | 0.21 | 1.46 | |
| Dividend 5 Year Growth Rate | -- | 2.28 | -6.24 | |
| Payout Ratio(TTM) | -- | 84.11 | 46.95 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 33.11 | 4.76 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 146.94 | 12.07 | |
| Sales - 5 Yr. Growth Rate | -- | 30.62 | 7.67 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 87.60 | -78.76 | 48.53 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -15.69 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 46.50 | 7.99 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 42.39 | 7.59 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.73 | 2.56 |
| Current Ratio (MRQ) | 3.52 | 6.61 | 3.63 |
| LT Debt to Equity (MRQ) | 0.00 | 24.43 | 13.24 |
| Total Debt to Equity (MRQ) | 0.00 | 28.63 | 17.38 |
| Interest Coverage (TTM) | -- | -156.28 | 35.72 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 55.88 | 55.29 | |
| Gross Margin - 5 Yr. Avg. | -- | 53.35 | 53.23 | |
| EBITD Margin (TTM) | -222.71 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -181.46 | 15.62 | |
| Operating Margin (TTM) | -223.02 | -962.40 | -0.76 | |
| Operating Margin - 5 Yr. Avg. | -- | -195.12 | 10.76 | |
| Pre-Tax Margin (TTM) | -214.14 | -855.13 | 1.14 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -199.56 | 10.90 | |
| Net Profit Margin (TTM) | -214.14 | -846.38 | -2.16 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -197.25 | 7.25 | |
| Effective Tax Rate (TTM) | -- | 14.83 | 20.78 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 19.08 | 24.32 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 1,012,356 | 23,266,505 | 732,349,814 | |
| Net Income/Employee (TTM) | -2,167,898 | -907,431 | 85,388,927 | |
| Receivable Turnover (TTM) | -- | 17.77 | 5.94 | |
| Inventory Turnover (TTM) | -- | 2.86 | 3.70 | |
| Asset Turnover (TTM) | 0.12 | 0.48 | 0.87 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -25.63 | -2.28 | 10.32 | |
| Return on Assets - 5 Yr. Avg. | -- | 2.92 | 10.99 | |
| Return on Investment (TTM) | -32.67 | -3.73 | 13.13 | |
| Return on Investment - 5 Yr. Avg. | -- | 2.73 | 14.20 | |
| Return on Equity (TTM) | -41.04 | -5.79 | 15.07 | |
| Return on Equity - 5 Yr. Avg. | -- | -4.40 | 15.53 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -53.34 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Loxo Oncology Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- Loxo-Bayer cancer drug gets priority review from FDA
- Loxo-Bayer cancer drug gets priority review from FDA
- Loxo Oncology's targeted RET drug shows promise in early trial
- CORRECTED-UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial
- Loxo Oncology's targeted RET drug shows promise in early trial
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 243 |
| Total Shares Held: | 31,047,988 |
| 3 Mo. Net Change: | -1,296,593 |
| # New Positions: | 9 |
| # Closed Positions: | 1 |
| # Increased Positions: | 23 |
| # Reduced Positions: | 12 |
| # Net Buyers: | 11 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.